Literature DB >> 8205663

Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women.

D M Gilligan1, A A Quyyumi, R O Cannon.   

Abstract

BACKGROUND: Estrogen replacement therapy has been associated with a reduction in cardiovascular events in postmenopausal women. One of the mechanisms responsible may be a beneficial effect of estrogen on coronary vascular function. We therefore studied the short-term effects of estrogen on coronary artery dimensions and microvascular resistance in postmenopausal women. METHODS AND
RESULTS: Twenty postmenopausal women 61 +/- 7 years old participated in this study. Seven had angiographic evidence of atherosclerosis of the left coronary artery. Coronary artery diameters were measured by quantitative coronary angiography. Blood flow velocity was measured with a Doppler wire placed in a proximal left coronary artery segment. Left coronary artery infusions of acetylcholine (range, 10(-8) to 10(-5) mol/L estimated delivered concentrations) and of adenosine (n = 18) and sodium nitroprusside (n = 10) were performed before and during concomitant continuous intracoronary infusion of 17 beta-estradiol to test endothelium-dependent and independent vasodilation, respectively. Intracoronary infusion of estradiol increased coronary sinus estradiol levels from postmenopausal (16 +/- 11 pg/mL) to premenopausal (282 +/- 121 pg/mL) levels. Estradiol did not affect basal coronary artery diameter, blood flow, or resistance. Epicardial coronary artery constriction induced by acetylcholine infusion in the control study (maximum, 10 +/- 15% from baseline) was prevented during repeat acetylcholine infusion with concomitant estradiol administration (P < .001). Estradiol potentiated the vasodilator coronary microvascular response to acetylcholine as manifest by significantly greater coronary flow (P < .001) and lower coronary resistance (P < .02). The reduction in coronary resistance from baseline in response to acetylcholine was significantly potentiated by estradiol (P = .01), with a mean decrease in coronary vascular resistance during acetylcholine infusion of 20 +/- 38% before and 35 +/- 33% during concomitant estradiol administration. The effect of estradiol on coronary dynamics was similar in women with and women without angiographically apparent left coronary artery atherosclerosis and was most prominent in women with the most impaired responses to acetylcholine at both the epicardial (r = -.72, P < .001) and microvascular (r = -.59, P = .006) coronary artery levels. In contrast, estradiol did not affect the coronary epicardial or microvascular vasodilator responses to adenosine or sodium nitroprusside.
CONCLUSIONS: Physiological levels of 17 beta-estradiol acutely and selectively potentiate endothelium-dependent vasodilation in both large coronary conductance arteries and coronary microvasuclar resistance arteries of postmenopausal women. This effect may contribute to the reduction in cardiovascular events observed with estrogen replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8205663     DOI: 10.1161/01.cir.89.6.2545

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  51 in total

1.  Enhanced relaxation of porcine coronary arteries after acute exposure to a physiological level of 17beta-estradiol involves non-genomic mechanisms and the cyclic AMP cascade.

Authors:  H Teoh; R Y Man
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

2.  Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

3.  Hormone replacement therapy trials: an update.

Authors:  Claire S Duvernoy; Lori Mosca
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

Review 4.  Invasive assessment of the coronary circulation: intravascular ultrasound and Doppler.

Authors:  David E Newby; Keith A A Fox
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

5.  Oestrogen upregulates the sarcoplasmic reticulum Ca(2+) ATPase pump in coronary arteries.

Authors:  Brent J F Hill; Edwin Muldrew
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-06       Impact factor: 2.557

Review 6.  The Role of Estrogen and Estrogen Receptors on Cardiomyocytes: An Overview.

Authors:  Tao Luo; Jin Kyung Kim
Journal:  Can J Cardiol       Date:  2015-11-02       Impact factor: 5.223

7.  Implications of plasma concentrations of adiponectin in patients with coronary artery disease.

Authors:  Y Nakamura; K Shimada; D Fukuda; Y Shimada; S Ehara; M Hirose; T Kataoka; K Kamimori; S Shimodozono; Y Kobayashi; M Yoshiyama; K Takeuchi; J Yoshikawa
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

Review 8.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Estrogen inhibits the response-to-injury in a mouse carotid artery model.

Authors:  T R Sullivan; R H Karas; M Aronovitz; G T Faller; J P Ziar; J J Smith; T F O'Donnell; M E Mendelsohn
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

10.  Essential role of the 90-kilodalton heat shock protein in mediating nongenomic estrogen signaling in coronary artery smooth muscle.

Authors:  Guichun Han; Handong Ma; Rajesh Chintala; David J R Fulton; Scott A Barman; Richard E White
Journal:  J Pharmacol Exp Ther       Date:  2009-03-17       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.